|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Conclusions:</b> The self-monitoring of IBD activity with a combination of a rapid fecal calprotectin home test and a symptom questionnaire provides an option for individualized care for IBD patients.
|
31264494 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Purpose:</b> Inflammatory bowel disease-associated colorectal cancers (IBD-CRC) are associated with a higher mortality than sporadic colorectal cancers.
|
29950348 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
197 patients with UC and 302 with CD (499 with inflammatory bowel disease (IBD] whose disease started before age 20 years and whose age at time of study was less than 25 years were investigated, with two age- and sex-matched controls for each patient.
|
3685876 |
1987 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel diseases [IBD], ulcerative colitis [UC] and Crohn's disease [CD], are chronic intestinal disorders of unknown etiology.
|
19519444 |
2009 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inflammatory bowel disease (IBD) generally comprises Crohn's disease (CD) and ulcerative colitis (UC), and their main characteristic is the intestinal mucosa inflammation.
|
25996176 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is an additional or isolated manifestation.
|
26464403 |
2016 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] presenting in early childhood is extremely rare.
|
27302973 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is characterized by chronic inflammation of the gastrointestinal tract.
|
27381462 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] entails a high economic burden to society.
|
27571772 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is considered to result from the interplay between host and intestinal microbiota but its pathogenesis is incompletely understood.
|
27609529 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is a chronic disease which affects up to 0.5% of the population.
|
28453761 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is characterised by a disruption of immune homeostasis, which is tightly regulated to protect against harmful pathogens yet not react to commensal antigens.
|
28472424 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is associated with a 1.5- to 3-fold increased risk of venous thromboembolism [VTE] events.
|
29220427 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD], including ulcerative colitis and Crohn's disease, is a chronic and unpredictable condition characterised by alternating periods of remission interspersed with relapses.
|
29529167 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] results particularly from an aberrance of CD4+ helper and regulatory T cells and comprises histopathologically chronic active enterocolitis with features reflecting both activity and chronicity of mucosal inflammation.
|
30137280 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel diseases [IBD] represent a challenging health issue with a complex aetiology involving genetic and environmental parameters.
|
30295779 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is characterized by recurrent disease flares.
|
30371776 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] includes chronic, disabling and progressive conditions that need a complex approach and management.
|
30423033 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel diseases [IBD] are characterised by significant quality of life [QoL] impairment, as well as illness perception.
|
30517669 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is accompanied by lesions in the epithelial barrier, which allow translocation of bacterial products from the gut lumen to the host's circulation.
|
30590526 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] is a complex chronic inflammatory disease of the human gut with no clear aetiology.
|
30689780 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory bowel disease [IBD] places an economic strain on health systems due to expensive pharmaceutical therapy, risk of hospitalisation and surgery, and long-term monitoring.
|
30916775 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A dysregulated intestinal T cell response is presumed in patients with inflammatory bowel disease [IBD].
|
29211912 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A retrospective matched case-control study of adults with co-existent inflammatory bowel disease [IBD] and celiac disease was performed at a tertiary referral institution in North America.
|
29741603 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Accumulating evidence supports epigenetic modifications in mediating intestinal immunity in inflammatory bowel disease [IBD] pathogenesis.
|
26802082 |
2016 |